Surrozen, Inc./DE (NASDAQ:SRZN)
| Market Cap | 231.80M+162.7% |
| Revenue (ttm) | 11.51M-8.8% |
| Net Income | -332.13M-1889.2% |
| EPS | -44.29-218.2% |
| Shares Out | 7.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,729 |
| Open | 29.41 |
| Previous Close | 29.00 |
| Day's Range | 29.00 - 31.32 |
| 52-Week Range | 11.66 - 37.83 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 54.00(+74.19%) |
| Earnings Date | n/a |
Insiders here have filed 6 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating SRZN in the last 3 months, one vote each. Issuer-paid research is not counted.
Latest investor presentation
Ask Barron about SRZN
$SRZN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SRZN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SRZN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SRZN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SRZN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SRZN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SRZN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $9.09M |
| IWMiShares Russell 2000 ETF | $5.87M |
| JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF | $5.28M |
| VXFVanguard Extended Market ETF | $2.59M |
| IWOiShares Russell 2000 Growth ETF | $2.17M |
| VTWOVanguard Russell 2000 ETF | $1.39M |
Estimated from each fund’s disclosed top holdings × AUM
SRZN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SRZN’s recent data — informational, not investment advice